Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 November 2024 - 4:27AM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 7 November 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Choi Lai Christina Law |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Member of the Board of Directors |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
ADRs
|
|
|
|
Identification code |
NVO |
|
|
b) |
Nature of the transaction |
Purchase of ADRs |
|
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 697.24 |
1,400 ADRs |
|
|
|
d) |
Aggregated information
|
1,400 ADRs
DKK 1,054,226.88 |
|
|
e) |
Date of the transaction |
2024-11-06 |
|
|
f) |
Place of the transaction |
New York Stock Exchange |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to
drive change to defeat serious chronic diseases, built upon our
heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs
about 69,000 people in 80 countries and markets its products in
around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit
novonordisk.com, Facebook,
Instagram, X, LinkedIn
and YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656 azey@novonordisk.com
|
Frederik
Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
|
Ida
Schaap Melvold
+45 3077 5649 idmg@novonordisk.com
|
|
Company announcement No 82 /2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Nov 2023 to Nov 2024
